№ lp_1_12845
File format: docx
Character count: 19217
File size: 91 KB
This policy outlines NHS England’s decision to commission tenofovir alafenamide (TAF) as a treatment option for HIV-1 in adults and adolescents, focusing on clinical effectiveness and cost implications.
Year:
2025
Region / City:
England
Theme:
HIV Treatment, Antiretroviral Therapy
Document Type:
Policy Statement
Organization / Institution:
NHS England
Author:
NHS England
Target Audience:
Healthcare professionals, policy makers
Effective Period:
Ongoing from May 2025
Approval Date:
May 2025
Date of Last Update:
August 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region:
England
Subject:
HIV-1 treatment
Document type:
Clinical commissioning policy
Organization:
NHS England
Target audience:
Adults and adolescents living with HIV-1
Approved date:
2021
Drug reviewed:
Tenofovir alafenamide (TAF)
Treatment context:
Antiretroviral therapy (ART)
Purpose:
Funding and clinical guidance for TAF use
Evidence reviewed:
Comparative safety and efficacy versus TDF
Population:
Patients with contraindications to TDF or with complications during treatment
Year:
2017
Region / city:
Australia
Subject:
Chronic Hepatitis B, Antiviral Therapy
Document Type:
Submission for PBS listing
Agency / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
GILEAD SCIENCES
Target audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
22 February 2017
Amendment date:
Not specified
Year:
2021
Region:
England
Subject:
HIV-1 treatment
Document type:
Clinical commissioning policy
Organization:
NHS England
Target audience:
Adults and adolescents living with HIV-1
Approved date:
2021
Drug reviewed:
Tenofovir alafenamide (TAF)
Treatment context:
Antiretroviral therapy (ART)
Purpose:
Funding and clinical guidance for TAF use
Evidence reviewed:
Comparative safety and efficacy versus TDF
Population:
Patients with contraindications to TDF or with complications during treatment
Year:
2017
Region / city:
Australia
Subject:
Chronic Hepatitis B, Antiviral Therapy
Document Type:
Submission for PBS listing
Agency / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
GILEAD SCIENCES
Target audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
22 February 2017
Amendment date:
Not specified
Year:
2026
Region:
Not specified
Document type:
Supplementary material / Research data
Methods:
LC-MS/MS, IP–HILIC–MS/MS
Analytes:
Tenofovir (TFV), Tenofovir-diphosphate (TFV-DP)
Sample types:
Urine, Dried Blood Spots (DBS)
Target population:
Participants on antiretroviral therapy (ART)
Measured variables:
Urine TFV concentration, DBS TFV-DP concentration, POC TFV results, self-reported adherence, viral load, drug resistance
Instrument:
Agilent HPLC coupled to AB Sciex 5500 triple quadrupole mass spectrometer
Software:
Analyst v1.6.2
Detection method:
Negative-ion multiple reaction monitoring (MRM)
Tables included:
S1, S2, S3, S4
Year:
2018
Region / city:
United Kingdom, Ireland
Subject:
Medicine information
Document type:
Patient information leaflet
Organization:
HIV Pharmacy Association (HIVPA)
Author:
HIV Pharmacy Association (HIVPA)
Target audience:
Patients switching from Atripla to generic tenofovir, emtricitabine, and efavirenz
Effective period:
From February 2018
Approval date:
February 2018
Date of changes:
Not mentioned
Contact:
Telephone number: [Provided in document]
Authors:
Brendan J. McMullan; Anita J. Campbell; Christopher C. Blyth; Jonathan C. McNeil; Christopher P. Montgomery; Steven Y. C. Tong; Asha C. Bowen
Type of document:
Narrative review article
Topic:
Pediatric Staphylococcus aureus bacteremia
Population:
Neonates, children and adolescents
Medical specialty:
Infectious Diseases
Methods:
Systematic appraisal of published literature
Data sources:
PubMed and Medline
Search period:
January 1960 – 31 December 2018
Geographic context:
High-income countries
Funding source:
No funding received
Conflict of interest:
None declared
Clinical scope:
Community-acquired and healthcare-associated bacteremia
Year:
2023
Region / City:
Canberra, Australia
Topic:
Paediatric intravenous extravasation management
Document Type:
Guideline
Organization:
Canberra Health Services
Author:
Expert clinical reference groups
Target Audience:
Clinicians in paediatric care
Period of validity:
Ongoing
Approval Date:
7 December 2023
Amendment Date:
26 August 2024
Year:
2021
Region:
England
Subject:
HIV-1 treatment
Document type:
Clinical commissioning policy
Organization:
NHS England
Target audience:
Adults and adolescents living with HIV-1
Approved date:
2021
Drug reviewed:
Tenofovir alafenamide (TAF)
Treatment context:
Antiretroviral therapy (ART)
Purpose:
Funding and clinical guidance for TAF use
Evidence reviewed:
Comparative safety and efficacy versus TDF
Population:
Patients with contraindications to TDF or with complications during treatment
Year:
2025
Region / City:
Canberra
Topic:
Medical Procedures, Oncology, Hematology
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Author:
Canberra Health Services
Target Audience:
Healthcare professionals involved in chemotherapy administration
Effective Period:
Ongoing
Approval Date:
2025-01-01
Date of Changes:
2025-01-01
Year:
2024
Region / city:
Canberra, ACT
Theme:
Asthma, Paediatrics, Clinical Guidelines
Document Type:
Clinical Guideline
Organization / institution:
Canberra Health Services
Author:
Paediatric Improvement Collaborative (PIC)
Target Audience:
Healthcare professionals, Paediatricians, Clinical staff
Effective period:
Indefinite
Approval date:
21/11/2024
Amendment date:
21/11/2024
Superseded document:
CHS21/253 Acute Asthma - Paediatrics (infants, children and adolescents)
Acknowledgment:
Ngunnawal people as traditional custodians of the ACT
Context:
Clinical guideline for the assessment and management of paediatric asthma within the Canberra Health Services Network.
Year:
2023
Region / City:
Canberra
Topic:
Behavioral Health, Pediatric Care
Document Type:
Procedure
Institution:
Canberra Health Services
Author:
Not specified
Target Audience:
Medical and healthcare professionals, specifically those in Emergency Department and Mental Health Services
Period of Application:
Ongoing, as part of interim procedure
Approval Date:
Not specified
Date of Changes:
Not specified
Organization:
Canberra Health Services
Type of document:
Clinical guideline
Topic:
Dental fissure sealants and fissure protection
Population:
Children and adolescents
Target audience:
Dental practitioners
Region:
Australia
Healthcare sector:
Oral health services
Clinical focus:
Caries prevention and early intervention
Materials covered:
Resin-based sealants; glass ionomer cement sealants
Scope of application:
Public oral health services
Evidence base:
Research studies and professional guidelines
Includes procedures:
Yes
Includes risk assessment:
Yes
Includes attachments:
Yes
Year:
2023
Region / City:
Canberra
Topic:
Pediatric Tube Feeding
Document Type:
Guideline
Organization / Institution:
Canberra Health Services Network
Author:
Canberra Health Services Policy Team
Target Audience:
CHS Network clinicians, pediatricians, and families of patients under pediatric care
Action Period:
Ongoing
Approval Date:
14/07/2023
Amendment Dates:
22/03/2024, 05/08/2024
Year:
2023
Region / city:
Canberra
Topic:
Medical Procedure, Bleeding Disorders
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Author:
Canberra Health Services
Target Audience:
Medical and nursing staff involved in desmopressin administration
Period of validity:
Ongoing
Approval Date:
2023
Date of changes:
N/A
Note:
Year
Region / City:
Canberra
Subject:
Stoma care, Post-operative care
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Target Audience:
Healthcare professionals involved in stoma care
Description:
Procedure document for the management of patients with a stoma in Canberra Health Services, including pre-operative education, post-operative care, and various stoma-related issues across different patient groups.
Year:
2019
Region / City:
N/A
Topic:
Behavioral Health Services for Children and Adolescents
Document Type:
Service Description
Organization:
N/A
Author:
N/A
Target Audience:
Healthcare Providers, Caregivers, Policy Makers
Effective Period:
Starting 7/1/2019
Approval Date:
N/A
Amendment Date:
N/A
Year:
2023
Region / City:
USA
Topic:
Hypertriglyceridemia, Genetic Disorders, Pediatrics
Document Type:
Research Article
Author:
Amy S. Shah, MD, MS, FNLA, Don P. Wilson, MD, FNLA
Target Audience:
Medical professionals, researchers, healthcare providers
Effective Period:
2023
Approval Date:
February 22, 2023
Date of Modifications:
N/A
Year:
2021
Region/Institution:
University of Wisconsin, University of Minnesota, University of Connecticut, University of Maryland, USA
Document Type:
Supplementary material
Authors:
Guanmin Liu, Na Zhang, Jia Yuan Teoh, Christine Egan, Thomas A. Zeffiro, Richard J. Davidson, Karina Quevedo
Corresponding Author:
Karina Quevedo, [email protected]
Target Population:
Depressed adolescents and healthy controls
Study Method:
fMRI, Emotional Self-Other Morph-Query (ESOM-Q) task, behavioral measures
Sample Size:
81 depressed youth, 37 healthy controls
Variables Measured:
Depression severity, self-compassion, response time, accuracy, fMRI activity
Demographics:
Age, sex, race/ethnicity, puberty stage, household income, parental marital status
Medication Use:
Antidepressant, antipsychotic, mood stabilizer, stimulant, anxiolytic